Retention of Vaccine-Mediated Humoral Immunity in the Post-Therapy Pediatric Oncology Population
Objective
1. To determine the proportion of pediatric cancer patients who have lost humoral immunity to selected previously received vaccines by end of therapy a. To determine the proportion of this group who regain vaccine-mediated immunity at 6 and 12 months off therapy 2. To determine the rate of response to re-vaccination with a single dose of selected vaccines in patients who are still seronegative 12 months off therapy 3. To determine the rate of response to re-vaccination with the complete vaccine series in patients who do not seroconvert after a single booster of selected vaccines 4. To perform a cost-benefit analysis comparing universal re-vaccination after completion of therapy with serologic studies and re-vaccination to selected vaccines only
